Aeglea aims to raise $60M for treating rare diseases

Aeglea BioTherapeutics Inc., an Austin-based biotechnology company developing treatments for rare genetic diseases and cancer, plans to raise $60 million with a new stock offering. The company on Feb. 5 agreed to sell 3.5 million shares of common stock to underwriters at $8 per share, plus pre-funded warrants to purchase up to 3.75 million more shares. Those underwriters will also have the option to buy up to 1,125,000 more shares. Aeglea (Nasdaq: AGLE) expects the offering to close Feb. 8 and…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news